Three (42.8%) patients in the non-progressive group and 11 (55%) patients in the progressive group had comorbidites. Six (85.7%) patients in the non-progressive group and 18 (90%) patients in the progressive group received hydroxychloroquine therapy. Nine (45%) patients in the progressive group had favipiravir treatment while it was started in 1 (14.3%) patient in the non-progressive group. No significant differences of comorbidities and treatment were found between the two groups of patients (p > 0.05).